Park et al. explored the interaction between NOXs and pharmacological inhibitors in stroke treatment, specifically focusing on the effects of inhibitors of poly(ADP-ribose) polymerase (PARP) and inducible nitric oxide synthase (iNOS) on stroke outcomes [66]. The gene discussed is PARP1; the disease is stroke disorder.